SLC5A2 and chronic kidney disease: In this cost-effectiveness analysis, population-wide screening for CKD combined with sodium-glucose cotransporter 2 inhibitors yielded larger reductions in kidney failure incidence and gains in life expectancy among non-Hispanic Black adults compared with Hispanic adults, non-Hispanic White adults, and adults from additional racial and ethnic groups (ie, Asian and multiracial individuals and those self-reporting other race and ethnicity).